Neuren Pharmaceuticals Ltd has released a press release.
Neuren and Lanstead agree to pause settlements for 120 days
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Neuren receives initial payment of US$10 million from ACADIA
- Neuren and ACADIA announce agreement for North America
- Announcement of buy-back - Appendix 3C
- Neuren announces investment and exclusive negotiation period
- First patent in Japan granted for Neurens trofinetide
Later from Neuren Pharmaceuticals
- Trofinetide ex-North America exclusive negotiation period
- NNZ-2591 positive effects in Phelan-McDermid syndrome model
- Preliminary Final Report and statutory accounts
- Neurens Rett syndrome Phase 2 trial published in Neurology
- Update on development plan for NNZ-2591
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals